Author name: Leonardo Arias

Edwards’ TAVR results in moderate aortic stenosis drew applause from meeting attendees, while Medtronic’s renal denervation and Abbott’s left atrial appendage closure devices also produced positive study findings.

CEO Ivan Tornos did not attribute the company’s performance in knees to a broader market slowdown, as competitor Stryker did last week.

AbbVie’s $100 million upfront cash payment will purchase global rights to Nxera’s deprioritized oral small molecule, which has already completed Phase 1 testing.

Philips will pay 288 million euros to settle an investigation related to its recall of millions of sleep and respiratory devices.

Patients say they’re open to doctors using AI for more administrative tasks, but they’re less enthusiastic about using it for diagnosing or claims adjudication, according to a new survey.

The breakup, which will separate Aetna and Caremark from CVS’ retail pharmacies, is an indictment of the dogma that bigger is always better in the healthcare industry.

Sanofi has discontinued an early-stage STAT6 degrader program licensed from Nurix Therapeutics, a decision analysts say is related to the asset itself or Sanofi’s strategic reprioritization rather than the drug class more broadly.

With the first Phase 3 data expected for Amgen’s MariTide next year, analysts are looking for evidence that the GLP-1 candidate is tolerable. Meanwhile, the company has begun testing an autoinjector formulation.

  Rascarse sin parar, lamerse las patas, otitis que vuelven o heces blandas de forma crónica: detrás de muchos de estos problemas puede haber una reacción adversa al alimento. No es lo más frecuente en la consulta general, pero sí en perros con problemas de …

Speaking on third quarter earnings calls this week, Novo and Pfizer’s CEOs see little change to their Most Favored Nation drug pricing deals, which were signed with the Trump administration last year.